TCR2 Therapeutics to Participate in Two Upcoming Conferences in September

Rhea-AI Summary

TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage immunotherapy company, announced that CFO Ian Somaiya will present updates at two virtual conferences this September. The presentations include:

• H.C. Wainwright 22^nd Annual Global Investment Conference on September 14, 2020, at 12:30 PM ET
• Cantor Global Healthcare Conference on September 17, 2020, at 9:20 AM ET

Investors can access live webcasts on the company’s website, with archived replays available for 30 days. TCR² develops novel T cell therapies targeting various cancers.

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, will present an update on Company progress at two upcoming conferences in September using a virtual platform.

• H.C. Wainwright 22^nd Annual Global Investment Conference on September 14, 2020 at 12:30pm ET
• Cantor Global Healthcare Conference on September 17, 2020 at 9:20am ET 

A live webcast of each presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What will TCRR present at the H.C. Wainwright conference?

TCRR will present updates on its progress at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 12:30 PM ET.

When is the Cantor Global Healthcare Conference for TCRR?

The Cantor Global Healthcare Conference for TCRR is scheduled for September 17, 2020, at 9:20 AM ET.

How can I watch TCRR's presentations online?

You can watch TCRR's presentations live via webcast on the Investors page of the company's website.

What is TCRR's lead product candidate?

TCRR's lead product candidate is TC-210, targeting mesothelin-positive tumors, and TC-110 for hematological malignancies.

What is TCRR's focus in cancer treatment?

TCRR focuses on developing novel T cell therapies for patients with solid tumors and hematological malignancies.